AJCC-8分期在EORTC1325/KEYNOTE-054试验中的预后与预测价值
在完全淋巴结清扫后的高危III期黑色素瘤患者中,AJCC-8分期对无复发生存期(RFS)有强预后价值,但无预测价值;帕博利珠单抗的RFS获益在各AJCC-8亚组中一致。
要点
- AJCC-8分期与RFS强相关,IIIB、IIIC、IIID对比IIIA的风险比分别为4.0、5.7、12.2。
- AJCC-8分期对治疗比较无预测意义(交互作用P=0.68)。
- 帕博利珠单抗在各AJCC-8亚组中均显示RFS获益。
核心结论
- AJCC-8分期对RFS有强预后价值,但对帕博利珠单抗与安慰剂的治疗比较无预测价值。
研究设计与样本
- EORTC1325/KEYNOTE-054双盲III期试验,纳入AJCC-7 IIIA(排除淋巴结转移≤1 mm)、IIIB或IIIC(无移行转移)且完全淋巴结清扫后的患者1019例。
- 患者按1:1随机接受帕博利珠单抗200 mg或安慰剂每3周一次,共18剂,约1年。
主要发现
- 中位随访1.25年时,帕博利珠单抗在总人群延长RFS(1年RFS率75.4% vs 61.0%;HR 0.57;logrank P < 0.0001),且在AJCC-7亚组中一致。
- 按AJCC-8分期分布:IIIA 8%、IIIB 34.7%、IIIC 49.7%、IIID 3.7%、未知3.8%。
- AJCC-8分期与RFS强相关(IIIB、IIIC、IIID对比IIIA的HR分别为4.0、5.7、12.2),但无预测重要性(交互作用P=0.68)。
- 各AJCC-8亚组中帕博利珠单抗 vs 安慰剂的1年RFS率及HR(99%CI):IIIA 92.7% vs 92.5%(0.76 [0.11-5.43])、IIIB 79.0% vs 65.5%(0.59 [0.35-0.99])、IIIC 73.6% vs 53.9%(0.48 [0.33-0.70])、IIID 50.0% vs 33.3%(0.69 [0.24-2.00])。
临床怎么用
- AJCC-8分期可用于高危III期黑色素瘤完全切除后的预后分层,但不应用来筛选帕博利珠单抗辅助治疗获益人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The American Joint Committee on Cancer-8 (AJCC) classification of melanoma was implemented in January 2018. It was based on data gathered when checkpoint inhibitors were not used as adjuvant therapy in stage III melanoma. The European Organization for Research and Treatment of Cancer (EORTC) 1325/KEYNOTE-054 double-blind phase III trial evaluated pembrolizumab vs placebo in AJCC-7 stage IIIA (excluding lymph node metastasis ≤1 mm), IIIB or IIIC (without in-transit metastasis) patients after complete lymphadenectomy. PATIENTS, METHODS AND RESULTS: Patients (n = 1019) were randomised 1:1 to pembrolizumab 200 mg or placebo every 3 weeks (total of 18 doses, ∼1 year). At 1.25-year median follow-up, pembrolizumab prolonged relapse-free survival (RFS) in the total population (1-year RFS rate: 75.4% vs 61.0%; hazard ratio [HR] 0.57; logrank P < 0.0001) and consistently in the AJCC-7 subgroups. Prognostic and predictive values of AJCC-8 for RFS were evaluated in this study. Patient distribution according to the AJCC-8 stage subgroups was 8% (IIIA), 34.7% (IIIB), 49.7% (IIIC), 3.7% (IIID) and 3.8% (unknown). AJCC-8 classification was strongly associated with RFS (HRs for stage IIIB, IIIC and IIID vs IIIA were 4.0, 5.7 and 12.2, respectively) but showed no predictive importance for the treatment comparison regarding RFS (test for interaction: P = 0.68). The 1-year RFS rate for pembrolizumab vs placebo and the HRs (99% confidence interval) within each AJCC-8 subgroup were as follows: stage IIIA (92.7% vs 92.5%; 0.76 [0.11-5.43]), IIIB (79.0% vs 65.5%; 0.59 [0.35-0.99]), IIIC (73.6% vs 53.9%; 0.48 [0.33-0.70]) and IIID (50.0% vs 33.3%; 0.69 [0.24-2.00]). CONCLUSIONS: AJCC-8 staging had a strong prognostic importance for RFS but no predictive importance: the RFS benefit of pembrolizumab was observed across AJCC-8 subgroups in resected high-risk stage III melanoma patients.
引用
- Eggermont AMM, Blank CU, Mandala M, et al. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. Eur J Cancer. 2019. PMID: 31200321. doi:10.1016/j.ejca.2019.05.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。